Clinical trials: Spectrum
Transcranial Direct Current Stimulation, Smoking, Cigarette
tDCS and Cognitive Training Intervention for Chronic Smokers With Schizophrenia
This study is being done to develop new methods to help smokers with schizophrenia to successfully reduce their smoking and/or quit. This is not a treatment study, but will help find new techniques to create better treatments.
- Conditions
- Transcranial Direct Current Stimulation, Smoking, Cigarette, Schizophrenia
- Trial name
- TACTICSS (NCT03588728)
- Testing
- Transcranial Direct Current Stimulation, Cognitive Remediation (CR)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Bipolar Disorder
Mobile Self-Tracking of Mental Health
Serious mental illnesses require years of monitoring and adjustments in treatment. Stress, substance abuse or reduced medication adherence cause rapid worsening of symptoms, with consequences that include job loss, homelessness…
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Post-traumatic Stress Disorder
- Trial name
- NCT05023252
- Testing
- mobile application
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- VA Office of Research and Development
Autism Spectrum Disorder, Gastrointestinal Symptoms
Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder
This protocol is a blinded randomized controlled study of the effects of BB-12 with LGG at different doses in 70 healthy children with autism spectrum disorders at lower and higher doses over an 56-day period and a 28- day…
- Trial name
- NCT03514784
- Testing
- BB-12 with LGG (Higher Dose), BB-12 with LGG (Lower Dose)
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Schizophrenia
An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia
The purpose of this study is to evaluate the long-term treatment efficacy, and safety of risperidone long-acting injection in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- NCT01894984
- Testing
- Risperidone, Oral atypical anti-psychotic
- Volunteers
- 640 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia
A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia
There is pilot data to suggest the therapeutic value of rTMS applied to the left prefrontal cortex in the treatment of negative symptoms.
- Trial name
- rTMS (NCT00168311)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Australia
- Volunteers
- 22 people
- Sponsor
- The Alfred
Metabolic Evaluation, Cardiac Complications
Metabolic and Clinical Effect of Alpha-lipoic Acid Administration in Schizophrenic Subjects
The therapeutic use of ALA in schizophrenia has recently been investigated in human populations. A case series explored the effiacy of ALA as a novel agent to treat antipsychotic-induced obesity, at a dose of 1200 mg/d (range…
- Trial name
- NCT06787781
- Testing
- Alpha Lipoic Acid
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- University of Messina
Schizophrenia
A Physical Dependence Study in Schizophrenia
The purpose of this study is to determine whether or not people with schizophrenia who take LY2140023 become physically dependent on it, and experience a series of symptoms such as craving to have the drug when they stop using…
- Trial name
- NCT01452919
- Testing
- LY2140023
- Where
- 10 sites in United States, Greece
- Volunteers
- 123 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia
The purpose of this study is to evaluate the effectiveness and safety of Extended Release Osmotic Controlled-Release Oral Delivery System (OROS) Paliperidone compared to placebo in patients with Schizophrenia.
- Trial name
- NCT00396565
- Testing
- ER OROS paliperidone, Olanzapine
- Where
- 56 sites in Japan
- Volunteers
- 394 people
- Sponsor
- Janssen Pharmaceutical K.K.
PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorder
Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation
Background: PIK3CA-related overgrowth spectrum (PROS) is caused by changes in the PIK3CA gene. This gene makes a protein that communicates with other proteins in the body to cause cells to grow.
- Conditions
- PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorder, Genetics
- Trial name
- NCT02428296
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Cognitive Behavioral Therapy, Autism Spectrum Disorder
Parent-Led Cognitive-Behavioral Teletherapy for Anxiety in Youth With ASD
This study implements an anxiety-focused, parent-led, therapist-assisted cognitive behavioral teletherapy for parents of youth with ASD and anxiety.
- Conditions
- Cognitive Behavioral Therapy, Autism Spectrum Disorder, Anxiety Disorders, Obsessive-Compulsive Disorder
- Trial name
- NCT04111874
- Testing
- Cognitive Behavioral Teletherapy LTA, Cognitive Behavioral Teletherapy STA
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Baylor College of Medicine
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00337662
- Testing
- olanzapine, risperidone
- Where
- 34 sites in United States, Argentina and 1 more
- Volunteers
- 628 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)
A study to evaluate the safety and efficacy of treatment with MK-8998 as compared to placebo and olanzapine for acutely psychotic patients with schizophrenia.
- Trial name
- NCT00827918
- Testing
- MK-8998, Comparator: Olanzapine
- Volunteers
- 216 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
This study will examine whether pretreatment with D-cycloserine before cognitive behavioral therapy can reduce impairments still present in people with stable cases of schizophrenia as well as determine which traits make…
- Trial name
- NCT00742079
- Testing
- D-cycloserine, Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
This study will be conducted to evaluate the efficacy, safety, and tolerability of GWP42003-P versus placebo in participants with schizophrenia experiencing inadequate response to ongoing antipsychotic treatment.
- Trial name
- NCT04421456
- Testing
- GWP42003-P
- Where
- 39 sites in United States, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Jazz Pharmaceuticals
Autism Spectrum Disorder
Comparison of DSM-IV-TR and DSM-5 for ASD
The study aim is to prospectively compare DSM-IV-TR and DSM-5 criteria for Autism Spectrum Disorder (ASD) in a sample of 250 children and adolescents who meet DSM-IV-TR criteria for ASD and 150 children and adolescents referred…
- Trial name
- NCT02296502
- Testing
- DSM
- Where
- 5 sites in United States
- Volunteers
- 439 people
- Sponsor
- University of Pittsburgh
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder
GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs
The purpose of this study is to examine the use of, and reaction to, one particular software application(GroundsKeeper) delivered on unique platform - Sifteo cubes (www.sifteo.com).
- Conditions
- Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Pervasive Developmental Disorder, Asperger's Disorder
- Trial name
- NCT01808066
- Testing
- Groundskeeper
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- CogCubed, Corp
Autistic Disorder
Sapropterin as a Treatment for Autistic Disorder
This study is intended to provide a definitive test of the hypothesis that elevating sapropterin (tetrahydrobiopterin, a cofactor for several key brain enzymes)concentrations in the CNS will result in measurable improvements in…
- Trial name
- NCT00850070
- Testing
- sapropterin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- The Children's Health Council
Schizophrenia
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
This study will determine the effectiveness of oral risperidone versus long-acting injectable risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00330551
- Testing
- Oral Risperidone, Risperidone in Long-Acting Injectable Form (Consta)
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Fragile X Syndrome
Trial of Sertraline to Treat Children With Fragile X Syndrome
This study is a control trial of sertraline (Zoloft) in fragile X syndrome children aged 2 years to 5 years 8 months old. The trial is six months long, and each participant will receive a series of tests at both the beginning and…
- Trial name
- NCT01474746
- Testing
- Sertraline
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Randi J. Hagerman, MD
Schizophrenia, Alzheimer Disease
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease…
- Trial name
- NCT02392468
- Testing
- BI 409306 25 mg, BI 409306 50 mg
- Where
- 3 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim